| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9311776 | Urology | 2005 | 4 Pages |
Abstract
The combination of estramustine, vinorelbine, and mitoxantrone is safe, well tolerated, and relatively active in patients with hormone-refractory prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Georgios Fotios Samelis, Haralambos Kalofonos, Adamos Adamou, Paris Kosmides, Dimosthenis Skarlos, Gerasimos Aravantinos, Christos Kiamouris, Oneynadum Adimchi, Georgios Fountzilas, Athanasios Meletios Dimopoulos,